Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Short Interest Update

Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) was the recipient of a significant drop in short interest in January. As of January 31st, there was short interest totalling 9,900 shares, a drop of 27.2% from the January 15th total of 13,600 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average trading volume of 34,700 shares, the days-to-cover ratio is presently 0.3 days.

Lakeshore Biopharma Stock Down 0.4 %

Shares of NASDAQ LSB traded down $0.01 during mid-day trading on Friday, hitting $2.40. The stock had a trading volume of 3,906 shares, compared to its average volume of 8,274. The company has a quick ratio of 0.90, a current ratio of 1.17 and a debt-to-equity ratio of 0.13. Lakeshore Biopharma has a 1 year low of $1.88 and a 1 year high of $11.20. The business has a 50 day moving average price of $2.78 and a two-hundred day moving average price of $3.70.

Hedge Funds Weigh In On Lakeshore Biopharma

A number of hedge funds have recently bought and sold shares of LSB. Barclays PLC purchased a new position in Lakeshore Biopharma in the 3rd quarter worth about $169,000. Hhlr Advisors LTD. purchased a new position in Lakeshore Biopharma in the 3rd quarter worth about $513,000. Finally, FMR LLC purchased a new position in Lakeshore Biopharma in the 3rd quarter worth about $803,000. Institutional investors own 52.64% of the company’s stock.

Lakeshore Biopharma Company Profile

LakeShore Biopharma Co, Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions.